Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Multiple-Ascending Doses of LY2979165 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 03 Feb 2017
At a glance
- Drugs MP 101 Mediti Pharma (Primary)
- Indications Bipolar disorders
- Focus Adverse reactions
- 03 Feb 2017 Results of two phase 1 single and multiple dose studies (NCT01248052 and NCT01383967) published in the British Journal of Clinical Pharmacology
- 13 Jun 2012 Actual patient number is 102 according to ClinicalTrials.gov.
- 21 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.